Literature DB >> 24012073

The prodrome and clinical risk for psychotic disorders.

Sandra M Goulding1, Carrie W Holtzman, Hanan D Trotman, Arthur T Ryan, Allison N Macdonald, Daniel I Shapiro, Joy L Brasfield, Elaine F Walker.   

Abstract

The psychosis prodrome offers great promise for identifying neural mechanisms involved in psychotic disorders and offers an opportunity to implement empirical interventions to delay, and ultimately ameliorate, illness onset. This article summarizes the literature on individuals in the putatively prodromal phase of psychosis/deemed at clinical high risk (CHR) for psychosis onset. Standardized measurement and manifestation of the CHR syndromes are discussed, followed by empirical findings that highlight the psychological deficits and biological abnormalities seen in CHR syndromes and psychotic disorders. Current controversies surrounding the diagnosis of CHR syndromes and issues related to the treatment of CHR individuals are also presented.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical high risk; Prodrome; Psychosis; Schizophrenia

Mesh:

Year:  2013        PMID: 24012073      PMCID: PMC4140174          DOI: 10.1016/j.chc.2013.04.002

Source DB:  PubMed          Journal:  Child Adolesc Psychiatr Clin N Am        ISSN: 1056-4993


  66 in total

Review 1.  Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis.

Authors:  Hiroyuki Uchida; Hiroyoshi Takeuchi; Ariel Graff-Guerrero; Takefumi Suzuki; Koichiro Watanabe; David C Mamo
Journal:  J Clin Psychopharmacol       Date:  2011-08       Impact factor: 3.153

2.  Gray matter alterations related to P300 abnormalities in subjects at high risk for psychosis: longitudinal MRI-EEG study.

Authors:  Paolo Fusar-Poli; Nicolas Crossley; James Woolley; Francesco Carletti; Rocio Perez-Iglesias; Matthew Broome; Louise Johns; Paul Tabraham; Elvira Bramon; Philip McGuire
Journal:  Neuroimage       Date:  2010-12-01       Impact factor: 6.556

3.  Increased stress-induced dopamine release in psychosis.

Authors:  Romina Mizrahi; Jean Addington; Pablo M Rusjan; Ivonne Suridjan; Alvina Ng; Isabelle Boileau; Jens C Pruessner; Gary Remington; Sylvain Houle; Alan A Wilson
Journal:  Biol Psychiatry       Date:  2011-11-30       Impact factor: 13.382

4.  Startle reactivity and prepulse inhibition in prodromal and early psychosis: effects of age, antipsychotics, tobacco and cannabis in a vulnerable population.

Authors:  Kristin S Cadenhead
Journal:  Psychiatry Res       Date:  2011-05-08       Impact factor: 3.222

5.  Axis I diagnoses and transition to psychosis in clinical high-risk patients EPOS project: prospective follow-up of 245 clinical high-risk outpatients in four countries.

Authors:  Raimo K R Salokangas; Stephan Ruhrmann; Heinrich Graf von Reventlow; Markus Heinimaa; Tanja Svirskis; Tiina From; Sinikka Luutonen; Georg Juckel; Don Linszen; Peter Dingemans; Max Birchwood; Paul Patterson; Frauke Schultze-Lutter; Joachim Klosterkötter
Journal:  Schizophr Res       Date:  2012-03-31       Impact factor: 4.939

6.  Diagnosing schizophrenia in the initial prodromal phase.

Authors:  J Klosterkötter; M Hellmich; E M Steinmeyer; F Schultze-Lutter
Journal:  Arch Gen Psychiatry       Date:  2001-02

Review 7.  Stress and psychosis: towards the development of new models of investigation.

Authors:  Lisa J Phillips; Shona M Francey; Jane Edwards; Nancy McMurray
Journal:  Clin Psychol Rev       Date:  2006-12-13

Review 8.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

9.  Antisaccade task performance in patients at ultra high risk for developing psychosis.

Authors:  Dorien Nieman; Hiske Becker; Reinaud van de Fliert; Niels Plat; Lo Bour; Hans Koelman; Maria Klaassen; Peter Dingemans; Maurice Niessen; Don Linszen
Journal:  Schizophr Res       Date:  2007-07-26       Impact factor: 4.939

Review 10.  Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review.

Authors:  James M Stone; Paul D Morrison; Lyn S Pilowsky
Journal:  J Psychopharmacol       Date:  2007-01-26       Impact factor: 4.153

View more
  6 in total

Review 1.  Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model.

Authors:  Felipe V Gomes; Millie Rincón-Cortés; Anthony A Grace
Journal:  Neurosci Biobehav Rev       Date:  2016-05-24       Impact factor: 8.989

2.  Understanding the schizophrenia prodrome.

Authors:  Manju George; Shreemit Maheshwari; Suhas Chandran; J Shivananda Manohar; T S Sathyanarayana Rao
Journal:  Indian J Psychiatry       Date:  2017 Oct-Dec       Impact factor: 1.759

3.  Prodromes and Preclinical Detection of Brain Diseases: Surveying the Ethical Landscape of Predicting Brain Health.

Authors:  Nathan S Ahlgrim; Kristie Garza; Carlie Hoffman; Karen S Rommelfanger
Journal:  eNeuro       Date:  2019-07-25

Review 4.  Oxidative-Antioxidant Imbalance and Impaired Glucose Metabolism in Schizophrenia.

Authors:  Amira Bryll; Justyna Skrzypek; Wirginia Krzyściak; Maja Szelągowska; Natalia Śmierciak; Tamas Kozicz; Tadeusz Popiela
Journal:  Biomolecules       Date:  2020-03-02

5.  Psychiatric Diagnoses and Treatment Preceding Schizophrenia in Adolescents Aged 9-17 Years.

Authors:  Christina D Kang-Yi; Brian Chao; Shelly Teng; Jill Locke; David S Mandell; Yin-Ling Irene Wong; C Neill Epperson
Journal:  Front Psychiatry       Date:  2020-06-04       Impact factor: 4.157

6.  Improving metabolic and cardiovascular health at an early psychosis intervention program in vancouver, Canada.

Authors:  Diane H Fredrikson; Heidi N Boyda; Lurdes Tse; Zachary Whitney; Mark A Pattison; Fred J Ott; Laura Hansen; Alasdair M Barr
Journal:  Front Psychiatry       Date:  2014-09-05       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.